Castration-Resistant Prostate Cancer: Targeted Therapies and Individualized Treatment

Several novel therapies for castration-resistant prostate cancer targeted to androgen receptor–mediated and non–androgen receptor–mediated pathways that have recently entered clinical trials are highlighted, including the molecular rationale and available clinical data, and emerging evidence on the potential of individualized therapy for castration-resistant prostate cancer is summarized.

[1]  M. Gleave,et al.  Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy , 2002, The Prostate.

[2]  C. Sawyers,et al.  In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). , 2001, Cancer research.

[3]  D. Agus,et al.  Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: A phase I/II, open-label study. , 2010 .

[4]  H. Kung,et al.  Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530 , 2008, Oncogene.

[5]  S. Steinberg,et al.  Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel , 2008, Molecular Cancer Therapeutics.

[6]  M. Morris,et al.  HE3235, a synthetic adrenal hormone disease-modifying agent, in castrate resistant prostate cancer (CRPC): Results of phase I/II clinical trial. , 2010 .

[7]  S. Steinberg,et al.  ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel , 2008, Clinical Cancer Research.

[8]  J. Humm,et al.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.

[9]  G. Rubanyi,et al.  Endothelins , 1991, The Lancet.

[10]  A. Tolcher,et al.  Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Kantoff,et al.  Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. , 1999, Urology.

[12]  E. Small,et al.  A Phase II Trial of Humanized Anti‐Vascular Endothelial Growth Factor Antibody for the Treatment of Androgen‐Independent Prostate Cancer , 2001 .

[13]  A. Tolcher,et al.  Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Mitch Dowsett,et al.  Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Kantoff,et al.  Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  G. Wilding,et al.  Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. , 2009, The Journal of urology.

[17]  H. Miyake,et al.  Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. , 2000, Cancer research.

[18]  N. James,et al.  Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration‐resistant prostate cancer and bone metastases who were pain‐free or mildly symptomatic for pain: a double‐blind, placebo‐controlled, randomized Phase II tria , 2010, BJU international.

[19]  S. Digumarthy,et al.  Isolation of rare circulating tumour cells in cancer patients by microchip technology , 2007, Nature.

[20]  W. Oh,et al.  A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone‐refractory prostate cancer who are refractory to docetaxel , 2008, Cancer.

[21]  I. Tannock,et al.  Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Matthias Egger,et al.  Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis , 2004, The Lancet.

[23]  P. Kantoff,et al.  A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Christophe Massard,et al.  Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer , 2009, Clinical Cancer Research.

[25]  V. Hasselblad,et al.  Systematic review and meta‐analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma , 2002, Cancer.

[26]  I. Tannock,et al.  Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. , 2005, Cancer research.

[27]  C. Tangen,et al.  Antiandrogen withdrawal in castrate‐refractory prostate cancer , 2008, Cancer.

[28]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[29]  D. Hicklin,et al.  A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity* , 2005, Journal of Biological Chemistry.

[30]  O. Cussenot,et al.  PTEN/MMAC1/TEP1 involvement in primary prostate cancers , 1998, Oncogene.

[31]  G. Sonpavde,et al.  Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  J. Jorcano,et al.  Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Herman,et al.  Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. , 1997, Cancer research.

[34]  C. Higano,et al.  A phase II study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody (MAb), against the insulin-like growth factor-1 receptor (IGF-IR), as monotherapy in patients with metastastic, asymptomatic castration-resistant prostate cancer (CRPC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  E. Latulippe,et al.  Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. , 2002, Cancer research.

[36]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[37]  Todd M Morgan,et al.  Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. , 2009, Current cancer drug targets.

[38]  J. LoPiccolo,et al.  Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[39]  M. Mullender,et al.  The Src Inhibitor AZD0530 Reversibly Inhibits the Formation and Activity of Human Osteoclasts , 2009, Molecular Cancer Research.

[40]  P. Kantoff,et al.  Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer , 2009, Clinical Cancer Research.

[41]  E. Corey,et al.  Inhibition of androstenediol-dependent LNCaP tumour growth by 17α-ethynyl-5α-androstane-3α, 17β-diol (HE3235) , 2009, British Journal of Cancer.

[42]  M. Gleave,et al.  Clusterin knockdown using the antisense oligonucleotide OGX‐011 re‐sensitizes docetaxel‐refractory prostate cancer PC‐3 cells to chemotherapy , 2008, BJU international.

[43]  H. Werner,et al.  The insulin-like growth factor-I receptor as an oncogene , 2009, Archives of physiology and biochemistry.

[44]  M. Gleave,et al.  A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. , 2005, Journal of the National Cancer Institute.

[45]  A. Adjei,et al.  Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors , 2007, Clinical Cancer Research.

[46]  A. Zannettino,et al.  Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis , 2009, Leukemia.

[47]  J. Squire,et al.  FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome , 2007, British Journal of Cancer.

[48]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[49]  C. Logothetis,et al.  Targeting Src signaling in metastatic bone disease , 2009, International journal of cancer.

[50]  Robert H. Bell,et al.  Increased Insulin-Like Growth Factor I Receptor Expression and Signaling Are Components of Androgen-Independent Progression in a Lineage-Derived Prostate Cancer Progression Model , 2004, Cancer Research.

[51]  Zhengxin Wang,et al.  Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. , 2008, Cancer research.

[52]  J. Cheng,et al.  Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. , 2005, Cancer research.

[53]  O. Melnyk,et al.  Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. , 1999, The Journal of urology.

[54]  F. Saad,et al.  A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer , 2007, Cancer.

[55]  E. Small,et al.  Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  N. Hay,et al.  Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. , 1998, Molecular endocrinology.

[57]  R. Vessella,et al.  The Prostate 68 : 861 ^ 871 ( 2008 ) RAD 001 ( Everolimus ) InhibitsGrowthof Prostate Cancer in theBone andthe Inhibitory EffectsAre IncreasedbyCombinationWithDocetaxel andZoledronicAcid , 2008 .

[58]  M. Shen,et al.  Pten inactivation and the emergence of androgen-independent prostate cancer. , 2007, Cancer research.

[59]  M. Ratain,et al.  A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies , 2009, Clinical Cancer Research.

[60]  C. Higano,et al.  A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors , 2007 .

[61]  H. Kung,et al.  Nonreceptor tyrosine kinases in prostate cancer. , 2007, Neoplasia.

[62]  J. Mossong,et al.  Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis , 2007, International journal of cancer.

[63]  Thomas J Mitchell,et al.  Src Family Kinase Activity Is Up-Regulated in Hormone-Refractory Prostate Cancer , 2009, Clinical Cancer Research.

[64]  P. Kantoff,et al.  Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[66]  D. Dearnaley,et al.  Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  K. Pienta,et al.  Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.

[68]  N. Carragher,et al.  Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530 , 2009, Molecular oncology.

[69]  Fei Huang,et al.  Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring , 2007, Genome Biology.

[70]  U. Banerji,et al.  Heat Shock Protein 90 as a Drug Target: Some Like It Hot , 2009, Clinical Cancer Research.

[71]  M. Loda,et al.  Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. , 1999, Cancer research.

[72]  I. Tannock,et al.  Concurrent and Sequential Administration of Chemotherapy and the Mammalian Target of Rapamycin Inhibitor Temsirolimus in Human Cancer Cells and Xenografts , 2009, Clinical Cancer Research.

[73]  S. Larson,et al.  Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[75]  K. Fizazi,et al.  The role of Src in prostate cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[76]  R. Grobholz,et al.  Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade. , 2005, Human pathology.

[77]  G. Wilding,et al.  A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer , 2011, Investigational New Drugs.

[78]  H. Scher,et al.  Targeting the androgen receptor pathway in prostate cancer. , 2008, Current opinion in pharmacology.

[79]  M. Gross,et al.  Phase I trial of RAD001 (R), bevacizumab (B), and docetaxel (D) for castration-resistant prostate cancer (CRPC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  F. Saad,et al.  PTEN genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancer , 2009, The Journal of pathology.

[81]  Gurkamal Chatta,et al.  A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study , 2009, Anti-cancer drugs.

[82]  J. Nelson,et al.  New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. , 1999, Urology.

[83]  Z. Hall.  Cancer , 1906, The Hospital.

[84]  C. Takimoto,et al.  Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes , 2009, Clinical Cancer Research.

[85]  J. Nelson,et al.  Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  R. Vessella,et al.  Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis , 2009, British Journal of Cancer.

[87]  Shunyou Wang,et al.  Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. , 2007, Cancer research.

[88]  L. Schwartz,et al.  Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. , 2009, European urology.

[89]  E. Small,et al.  Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer. , 2007, Urologic oncology.

[90]  T. Tammela,et al.  Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. , 2000, The Journal of urology.

[91]  P. Febbo,et al.  Genomic strategy for targeting therapy in castration-resistant prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  J. Nelson,et al.  Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate , 1995, Nature Medicine.

[93]  M. Gleave,et al.  Silencing Expression of the Clusterin/Apolipoprotein J Gene in Human Cancer Cells Using Small Interfering RNA Induces Spontaneous Apoptosis, Reduced Growth Ability, and Cell Sensitization to Genotoxic and Oxidative Stress , 2004, Cancer Research.

[94]  A. Borowsky,et al.  Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. , 2009, Cancer research.